Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER TEENS oral semaglutide versus placebo in pediatric type 2 diabetes
MOH_2020-10-13_009035Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing Oral semaglutide plus background therapy with Placebo plus background therapy (2 arms). Started Oct 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2020-10-13_009035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-10-13_009035.